Rosuvastatin is Superior to Simvastatin for LDL-C Reduction
Rosuvastatin achieves significantly greater LDL-cholesterol lowering than simvastatin at comparable doses, making it the preferred choice when more aggressive LDL-C reduction is needed. This superiority is consistently demonstrated across FDA-approved labeling data, clinical guidelines, and multiple real-world studies.
Evidence-Based Comparison
Direct Head-to-Head Data
The FDA label for rosuvastatin provides the most definitive comparative data from a multicenter study of 2,240 patients 1:
- Rosuvastatin 10 mg: -46% LDL-C reduction
- Simvastatin 10 mg: -28% LDL-C reduction
- Rosuvastatin 20 mg: -52% LDL-C reduction
- Simvastatin 20 mg: -35% LDL-C reduction
- Rosuvastatin 40 mg: -55% LDL-C reduction
- Simvastatin 40 mg: -39% LDL-C reduction
Rosuvastatin 10 mg reduced LDL-C significantly more than simvastatin 10 mg, 20 mg, and 40 mg (p<0.002) 1. This means a lower dose of rosuvastatin outperforms higher doses of simvastatin.
Guideline Classification
The 2018 AHA/ACC Cholesterol Guidelines classify statins by intensity based on expected LDL-C reduction 2:
High-Intensity (≥50% LDL-C reduction):
- Rosuvastatin 20-40 mg
- Simvastatin: None qualify
Moderate-Intensity (30-49% LDL-C reduction):
- Rosuvastatin 5-10 mg
- Simvastatin 20-40 mg
This classification reveals that even low-dose rosuvastatin (5-10 mg) achieves moderate-intensity effects, while simvastatin requires 20-40 mg to reach the same category. Notably, simvastatin 80 mg is not recommended by the FDA due to increased myopathy risk 2.
Real-World Clinical Performance
Magnitude of Difference
A 2025 retrospective study of 1,100 patients in primary care found rosuvastatin achieved the greatest mean LDL-C reduction, followed by atorvastatin, with simvastatin demonstrating significantly lower effectiveness (ANOVA, p<0.001) 3.
In a real-world electronic medical records study of 277 patients switched between statins, those switched to rosuvastatin achieved 18.4% additional LDL-C reduction versus only 5.8% with simvastatin (p=0.0003) 4. After adjusting for baseline covariates, rosuvastatin patients had 16.0% versus 8.8% reduction (p=0.0002).
Goal Attainment Rates
The SPACE ROCKET trial (1,263 post-MI patients) compared simvastatin 40 mg versus rosuvastatin 10 mg 5:
- Mean LDL-C: 2.03 mmol/L (78 mg/dL) with simvastatin vs. 1.94 mmol/L (75 mg/dL) with rosuvastatin (p=0.009)
- Achieving LDL-C <70 mg/dL: 37.8% with simvastatin vs. 45.0% with rosuvastatin (OR: 1.37, p=0.007)
- Achieving LDL-C <77 mg/dL: 38.7% with simvastatin vs. 47.7% with rosuvastatin (OR: 1.48, p=0.001)
Among diabetic patients, 72.8% on rosuvastatin achieved LDL-C <100 mg/dL versus only 36.8-67.4% on other statins including simvastatin (p<0.05) 6.
Clinical Decision Algorithm
When selecting between rosuvastatin and simvastatin:
For high-intensity statin therapy (≥50% LDL-C reduction needed):
- Choose rosuvastatin 20-40 mg
- Simvastatin cannot achieve this intensity safely
For moderate-intensity therapy (30-49% reduction needed):
- Rosuvastatin 5-10 mg is preferred over simvastatin 20-40 mg
- Provides equivalent or superior reduction at lower doses
For patients requiring LDL-C <70 mg/dL:
- Rosuvastatin significantly increases probability of goal attainment
- Simvastatin 40 mg leaves >60% of patients above target
For dose titration scenarios:
- More rosuvastatin patients remain at starting dose and achieve goals 7
- Simvastatin requires more frequent dose escalation
Important Caveats
Interindividual Variability
While rosuvastatin demonstrates superior average reductions, a 2026 study of 28,647 Chinese patients revealed profound interindividual variability—from >80% reductions to >200% increases on the same statin and dose 8. Over 30% of patients exhibited suboptimal response regardless of statin type, emphasizing the need for follow-up LDL-C monitoring rather than assuming guideline-predicted responses.
Asian Populations
The 2018 guidelines note that "certain Asian populations may have a greater response to certain statins" 2. A Korean study found that moderate-intensity statins (including rosuvastatin 10 mg and simvastatin 20 mg) achieved >50% LDL-C reduction in patients with baseline LDL-C ≥190 mg/dL 9, suggesting dose adjustments may be appropriate in these populations.
Safety Considerations
Simvastatin 80 mg carries FDA warnings for increased myopathy and rhabdomyolysis risk and should not be initiated or titrated to this dose 2. This effectively caps simvastatin's maximum safe intensity below rosuvastatin's capabilities.
Cost and Formulary Access
While both medications are now available generically, formulary restrictions may influence real-world prescribing. However, the superior efficacy of rosuvastatin translates to better goal attainment rates, potentially reducing need for additional lipid-lowering agents 3.